Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.

Abstract: The present invention provides a polynucleotide (ncp) which identifies and encodes a novel cysteine protease (NCP) expressed in cells of both the adrenal gland and human umbilical vein endothelium. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified NCP peptide, antibodies capable of binding to NCP, inhibitors which bind to NCP and pharmaceutical compositions based on NCP specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered ncp expression and which allow identification of such a condition. These assays utilize probes designed from ncp encoding or controlling nucleic acid sequences or antibodies specific for the NCP.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.

Abstract: The present invention provides a polynucleotide (icel) which identifies and encodes a human ice homolog (ICEL) expressed in lung cells and tissues. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified ICEL peptide, antibodies capable of binding to ICEL, inhibitors which bind to ICEL and pharmaceutical compositions based on ICEL specific antibodies or inhibitors. The invention specifically provides for diagnostic assays which identify a disorder or disease with altered icel expression which allows identification and monitoring of hospital patients. These assays utilize icel encoding or controlling nucleic acid sequences, fragments or oligomers thereof, or antibodies specific for the peptide.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.

Abstract: The present invention provides a polynucleotide (ncp) which identifies and encodes a novel cysteine protease (NCP) expressed in cells of both the adrenal gland and human umbilical vein endothelium. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified NCP peptide, antibodies capable of binding to NCP, inhibitors which bind to NCP and pharmaceutical compositions based on NCP specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered ncp expression and which allow identification of such a condition. These assays utilize probes designed from ncp encoding or controlling nucleic acid sequences or antibodies specific for the NCP.

Abstract: The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Abstract: The present provides a polynucleotide which identifies and encodes a novel human kallikrein (HKLP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding HKLP. The invention also provides for the use of substantially purified HKLP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of HKLP. Additionally, the invention provides for the use of antisense molecules to HKLP in pharmaceutical compositions for treatment of diseases associated with the expression of HKLP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding HKLP or anti-HKLP antibodies which specifically bind to HKLP.

Abstract: The present invention provides a polynucleotide (ncp) which identifies and encodes a novel cysteine protease (NCP) expressed in cells of both the adrenal gland and human umbilical vein endothelium. The present invention also provides for antisense molecules and oligomers designed from the nucleotide sequence or its antisense. The invention further provides genetically engineered expression vectors and host cells for the production of purified NCP peptide, antibodies capable of binding to NCP, inhibitors which bind to NCP and pharmaceutical compositions based on NCP specific antibodies or inhibitors. The invention specifically provides for diagnostic assays based on altered ncp expression and which allow identification of such a condition. These assays utilize probes designed from ncp encoding or controlling nucleic acid sequences or antibodies specific for the NCP.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new human interleukin-1 converting enzyme homolog (ICEY). The present invention also provides for antisense molecules to the nucleotide sequences which encode ICEY, expression vectors for the production of purified ICEY, antibodies capable of binding specifically to ICEY, hybridization probes or oligonucleotides for the detection of ICEY-encoding nucleotide sequences, genetically engineered host cells for the expression of ICEY, diagnostic tests for activation of monocyte/macrophages based on ICEY-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel pancreas-derived serpin (PDS) expressed in human pancreas. The present invention also provides for antisense molecules to the nucleotide sequences which encode PDS, expression vectors for the production of purified PDS, antibodies capable of binding specifically to PDS, hybridization probes or oligonucleotides for the detection of PDS-encoding nucleotide sequences, genetically engineered host cells for the expression of PDS, diagnostic tests based on PDS-encoding nucleic acid molecules and a pharmaceutical composition containing PDS capable of binding specifically to a serine protease.

Abstract: The present invention provides a polynucleotide (pdih) the partial sequence for which was initially isolated from a lung cDNA library and which identifies and encodes a novel human protein disulfide isomerase (PDIH). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding PDIH. The invention also provides for the use of purified PDIH and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the abnormal expression of PDIH. Additionally, the invention provides for the use of antisense molecules to pdih or inhibitors of PDIH in pharmaceutical compositions for treatment of diseases resulting secretion of PDIH.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a human homolog of rat elastase IV (HEIV) expressed in pancreas tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode HEIV, hybridization probes or oligonucleotides for the detection of HEIV-encoding nucleotide sequences, and a diagnostic test based on HEIV-encoding nucleic acid molecules. The present invention further provides for genetically engineered host cells for the expression of HEIV, biologically active HEIV, antibodies capable for binding specifically to HEIV, and treatment methods comprising administration of compounds, such antibodies or inhibitors, capable of binding HEIV to alter its activity.

Abstract: The present invention provides a polynucleotide which identifies and encodes a human cell death-associated protein (cdap) which was isolated from a rheumatoid synovium library. The invention provides for genetically engineered expression vectors and host cells comprising a nucleic acid sequence encoding CDAP. The invention also provides for the therapeutic use of purified CDAP, cdap or its antisense molecules, or CDAP inhibitors in pharmaceutical compositions and for treatment of conditions or diseases associated with expression of CDAP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, or fragments thereof, or antibodies which specifically bind to the polypeptide.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel serpin (CAPE) expressed in human hypothalamus. The present invention also provides for antisense molecules to the nucleotide sequences which encode CAPE, expression vectors for the production of purified CAPE, antibodies capable for binding specifically to CAPE, hybridization probes or oligonucleotides for the detection of CAPE-encoding nucleotide sequences, genetically engineered host cells for the expression of Cape, a pharmaceutical composition containing biologically active CAPE, a diagnostic test based on CAPE-encoding nucleic acid molecules, and treatment methods comprising administration of biologically active CAPE.

Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new human interleukin-1 converting enzyme homolog (ICEY). The present invention also provides for expression vectors for the production of purified ICEY, hybridization probes for the detection of ICEY-encoding nucleotide sequences, genetically engineered host cells for the expression of ICEY, diagnostic tests for ICEY or for polynucleotides encoding ICEY, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.